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Chronic kidney disease (CKD) is a global epidemic, but efforts
to reduce its burden have been less effective than for other non-
communicable diseases. Between 1990 and 2017, the global
age-standardized mortality rate fell by 41.3% for chronic ob-
structive pulmonary disease, 30.4% for cardiovascular disease,
14.9% for cancer, but by only 2.8% for CKD [1]. Importantly,
CKD is an independent risk factor for cardiovascular disease
(CVD), which is its most common endpoint [2]. Indeed, in a re-
cent analysis, almost 7% of global CVD burden was attributed
to impaired kidney function [3]. Identifying cardiovascular risk
early in CKD and assessing its response to treatments are key
unmet clinical challenges.
Circulating cardiac troponin is a strong independent predic-
tor of cardiovascular morbidity and mortality in individuals
with and without CVD [4]. We recently demonstrated that car-
diac troponin concentrations are reduced by statin therapy and,
importantly, the magnitude of this reduction is an independent
predictor of future coronary events [5]. This was the first de-
scription of a biomarker that can dynamically track cardiovas-
cular risk with time and raises the possibility that serial testing
may have a role in assessing response to a range of therapies.
Given increased troponin concentrations are associated with
higher blood pressure (BP) [6], a common feature of CKD [7],
we hypothesized that in those with CKD, troponin concentra-
tions may also be modified by BP-lowering therapies, a corner-
stone of CKD management. To explore this, we performed a
post hoc analysis of a previously reported randomized, double-
blind, placebo-controlled study that examined the systemic car-
diovascular and renal effects of a selective endothelin A (ETA)
receptor antagonist [8]. Endothelin receptor antagonism is a
potential novel therapy for CKD currently being studied for its
BP-, lipid- and proteinuria-lowering effects [9] as well as its
ability to improve patient outcomes [10].
In a randomized, double-blind, three-way crossover study,
27 participants with optimally managed and stable non-
diabetic proteinuric CKD received the selective ETA receptor
antagonist sitaxentan, nifedipine once daily or a matched
placebo for 6 weeks in addition to their usual medications.
There was a minimum 2-week washout period between phases.
All subjects completed all three phases of the study. Patient di-
agnoses were immunoglobulin-A (IgA) nephropathy (n¼ 14),
focal and segmental glomerulosclerosis (n¼ 6), membranous
nephropathy (n¼ 3), hypertensive nephrosclerosis (n¼ 2), re-
flux nephropathy, microhematuria of presumed glomerular ori-
gin (n¼ 1 for both) and one subject with an unknown cause for
their CKD. The mean age was 48 6 12 years, mean body mass
index was 29.3 6 4.6 kg/m2 and 23 participants were male. The
mean estimated glomerular filtration rate was 54 6 26 mL/min/
1.73 m2 and mean proteinuria was 2.0 6 1.7 g/day. Eighteen
(67%) participants were on statins and 24 (89%) were on either
an angiotensin converting enzyme inhibitor or an angiotensin
receptor blocker.
High-sensitivity cardiac troponin I concentrations (Abbott
Laboratories, Abbott Park, IL, USA) were measured in stored
plasma at baseline and at 3 and 6 weeks during each phase
(limit of detection 1.2 ng/L, interassay coefficient of variation
(CV) <10% at 4.7 ng/L) [11]. Low-density lipoprotein (LDL)
cholesterol was measured by a direct method using an enzy-
matic colorimetric assay; the limit of detection was 1.0 mg/dL
with an intra- and interassay CV of 1.4% and 2.2%, respectively.
Approval for the study was granted by the local ethics review
board and participants provided informed consent. The study
was performed in keeping with the principles outlined in the
Declaration of Helsinki.
At baseline, the median troponin concentration was 2.3 ng/L
(interquartile range 1.6–4.4), the mean systolic BP was
125 6 12 mmHg and the LDL cholesterol concentration was
103 6 32 mg/dL. There were no differences in any of these
parameters at the start of each phase (P> 0.05 for all). Whereas
placebo and nifedipine did not affect cardiac troponin, selective
ETA antagonism reduced troponin concentrations by
1.6 6 0.5 ng/L (27 6 19%) (P¼ 0.01 versus both placebo and
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nifedipine; Figure 1A). LDL cholesterol was unaffected by pla-
cebo or nifedipine, but ETA antagonism decreased this by
19 6 4 mg/dL (20 6 13%) (P< 0.001 versus both) [12].
While individual changes in systolic BP varied across each
study phase and were unrelated to changes in troponin concen-
tration (Figure 1B), decreases in LDL cholesterol were associ-
ated with reductions in troponin concentration on ETA
antagonism (Figure 1C). Interestingly, the troponin-lowering
effects of selective ETA receptor antagonism tended to be
greater in those already taking a statin (–2.0 6 0.8 versus –
0.7 6 0.1 ng/L without statin, P¼ 0.11; Figure 1D) as well as in
those patients prescribed a renin–angiotensin system blocker at
study entry (–1.8 6 0.6 versus –0.3 6 0.3 ng/L without treat-
ment, P¼ 0.04; Figure 1E).
Our observations suggest that troponin concentrations are
not reduced by BP-lowering therapies in CKD, at least not
within 6 weeks of initiating treatment. However, the LDL
cholesterol–lowering effect of ETA antagonism was associated
with a rapid and reproducible reduction in troponin concentra-
tion. These findings are consistent with our previous observations
[5] and suggest that LDL cholesterol may be an important deter-
minant of troponin concentration. While the mechanism
through which selective ETA receptor antagonism reduces LDL
cholesterol is unknown, our findings are novel and suggest that
ETA receptor antagonism has the potential to improve cardiovas-
cular health in those with optimally managed CKD by reducing
BP, lowering LDL cholesterol and reducing myocardial injury.
The recent Study of Diabetic Nephropathy with Atrasentan
(SONAR) study demonstrated the efficacy of atrasentan, an
ETA receptor antagonist, in slowing diabetic CKD progression
[10]. Interestingly, the benefits of atrasentan on CKD progres-
sion were seen regardless of proteinuria reduction, suggesting
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FIGURE 1: (A) Absolute change 6 standard error (SE) in cardiac troponin I after 3 and 6 weeks of treatment with placebo (blue), nifedipine
(green) and sitaxentan (red). (B) Percentage change in systolic BP and (C) LDL cholesterol plotted against the percent change in cardiac tropo-
nin across the three treatment arms. The numbers in each quadrant in (B) and (C) represent the number of patients (from a total of 27) that
achieved the relevant changes in the parameters shown by treatment. For example, 25 patients demonstrated a reduction in both LDL choles-
terol and troponin I compared to 9 with placebo and 10 with nifedipine (C). (D) Absolute change 6 SE in cardiac troponin I after 6 weeks of
treatment with sitaxentan in patients prescribed (dark blue) and not prescribed (light blue) a statin at baseline. (E) Absolute change 6 SE in
cardiac troponin I after 6 weeks of treatment with sitaxentan in patients prescribed ( dark blue) and not prescribed (light blue) a renin–angio-
tensin system blocker at baseline. *P< 0.01 versus placebo and nifedipine. Baseline cardiac troponin and LDL cholesterol levels were assessed
by one-way analysis of variance (ANOVA) for a period effect at the start of each treatment phase. Changes in troponin and LDL concentra-
tions from baseline were assessed using paired t-tests with Week 6 data. Changes in troponin and LDL concentrations between phases were
assessed using two-way ANOVA with Tukey’s multiple comparison test. Data were analysed in R (version 3.3.3; R Foundation, Vienna,
Austria). Significance was taken at the 5% level.
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additional mechanisms. Also, in this same study, atrasentan re-
duced the incidence of non-fatal stroke. Our current data sug-
gest that these beneficial effects of an ETA blocking approach
may relate to reductions in circulating LDL cholesterol and car-
diac troponin, although studies with longer follow-up to accrue
cardiovascular events are now required. ETA receptor antago-
nism offers a potential novel strategy to reduce cardiovascular
risk in patients with CKD and further investigation of its mech-
anistic links with LDL cholesterol and cardiac troponin are
merited. A Phase 2 study of selective ETA antagonism in combi-
nation with angiotensin II receptor blockade in patients with
proteinuric CKD is ongoing [13] and should help confirm the
current observations.
In this proof-of-concept study, improvements in these risk
factors were achieved despite high baseline use of statins and re-
nin–angiotensin system blockers. Further studies are required
to determine whether prolonged reductions in BP can alter left
ventricular mass and reduce cardiac troponin concentrations
and to establish the role of serial troponin testing in monitoring
the response to novel and established cardiovascular therapies
in those with and without CKD.
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